Status:
UNKNOWN
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
Lead Sponsor:
Fudan University
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This observational study is conducted to assess the utility of circulating tumor DNA in monitoring the response to pegylated liposomal doxorubicin in platinum-resistant ovarian cancer，and evaluate the...
Detailed Description
The goal of this study is to assess the utility of circulating tumor DNA in monitoring the response to pegylated liposomal doxorubicin in platinum-resistant ovarian cancer.This is a single-arm, single...
Eligibility Criteria
Inclusion
- Female, over 18 years of age;
- Patients with histopathological diagnosis of high-grade serous epithelial ovarian cancer;
- pathological report:phenotype of p53 mutation；or previous genetic tests of tumor tissue indicated TP53 gene mutations;
- ECOG≤ 2;
- Expected survival time ≥3 months;
- The subjects were able to understand the study process and voluntarily joined the study.
Exclusion
- Pregnant and lactating patients;
- Patients with severe or uncontrolled infections;
- Patients who are allergic or intolerant to the investigational drug;
- Patients who are enrolled in or within a month of another clinical trial.
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05976932
Start Date
August 1 2023
End Date
October 1 2024
Last Update
August 4 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.